Paxil® Linked To Birth Defects and Congenital Malformations
October 26, 2005
U.S. health officials and GlaxoSmithKline are warning doctors about the risk of major birth defects in infants born to women who take Paxil® during their first trimester of pregnancy.
GlaxoSmithKline, the manufacturer of Paxil®, recently conducted a study of major birth defects in infants born to women who took antidepressants (including Paxil®) during the first trimester of pregnancy. Preliminary results linked first-trimester Paxil®use to an increased risk of major birth defects. According to the FDA, Paxil® was linked to twice as many major birth defects as other antidepressants in the study. Most of the birth defects were heart related.
Other recent studies have revealed that women who took Paxil® during their first trimester were six times more likely to have an infant with omphalocele, a birth defect in which the infant's intestine or other abdominal organs protrude from the navel.
Paxil®, known as paroxetene, is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, obsessive-compulsive disorder, social anxiety disorder, and other mental health conditions. It is estimated that doctors wrote over 37 million Paxil® prescriptions in 2002 alone.
The FDA warns physicians to carefully weigh the potential risks and benefits of prescribing Paxil® to women during pregnancy and discuss the risks and treatment alternatives with their patients.
If you or someone you know took Paxil during pregnancy and had a child born with birth defects, and you wish to consult with us, please call Tara Sutton at 612-349-8577 or Kathy Neuman, Legal Nurse Consultant, at 612-349-8513. You can also send them an e-mail by clicking on this link: contact us.
 To read the study, go to http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp
Alwan S, Reefhuis J, Rasmussen S, et al., “Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects.” Birth Defects Research (Part A): Clinical and Molecular Teratology 2005 ;731:291.
The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.